Cargando…

Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study

Recently, apatinib has been shown to be effective in treating sarcoma. This study aimed to assess the safety and efficacy of apatinib in the treatment of patients with osteosarcoma after failed of standard multimodal therapy and to compare the therapeutic effects of apatinib on osteosarcoma between...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Zhichao, Gu, Zhiyuan, Wang, Xin, Liu, Zhiyong, Yao, Weitao, Wang, Jiaqiang, Zhang, Peng, Cai, Qiqing, Ge, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531132/
https://www.ncbi.nlm.nih.gov/pubmed/31083265
http://dx.doi.org/10.1097/MD.0000000000015650
_version_ 1783420764434726912
author Tian, Zhichao
Gu, Zhiyuan
Wang, Xin
Liu, Zhiyong
Yao, Weitao
Wang, Jiaqiang
Zhang, Peng
Cai, Qiqing
Ge, Hong
author_facet Tian, Zhichao
Gu, Zhiyuan
Wang, Xin
Liu, Zhiyong
Yao, Weitao
Wang, Jiaqiang
Zhang, Peng
Cai, Qiqing
Ge, Hong
author_sort Tian, Zhichao
collection PubMed
description Recently, apatinib has been shown to be effective in treating sarcoma. This study aimed to assess the safety and efficacy of apatinib in the treatment of patients with osteosarcoma after failed of standard multimodal therapy and to compare the therapeutic effects of apatinib on osteosarcoma between high-dose group and low-dose group. A total of 27 patients with osteosarcoma who received apatinib between January 2016 and August 2017 were retrospectively reviewed. Among the 27 patients, the objective response rate (ORR) and the disease control rate (DCR) were 25.93% and 66.67%, respectively. The median of progression-free survival (m-PFS) was 3.5 months (95% confidence interval [CI], 2.5–4.8 months), and the median of overall survival (m-OS) was 9.5 months (95% CI, 7.8–10.5 months). There was no statistically significant difference in ORR (36.36% vs 18.75%), DCR (63.64% vs 68.75%), m-PFS (4.3 months [95% CI, 1.8–7 months) vs 3.35 months (95% CI, 1.8–4 months]), and m-OS (9.5 months [95% CI, 7.8–10.5 months] vs 9.4 months [95% CI, 7.8–10.8 months]) (P > .05) between the high-dose group (the average dose was 659 mg/qd) and the low-dose group (the average dose was 516 mg/qd). Most of the adverse events (AEs) were in grade 1 or grade 2. The main AEs in grade 3 were hypertension, rash, weight loss, hand-foot syndrome, and diarrhea. Apatinib is safe and effective in the treatment of advanced osteosarcoma. We recommend that the initial dose of apatinib should be 500 mg/qd in the treatment of osteosarcoma.
format Online
Article
Text
id pubmed-6531132
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-65311322019-06-25 Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study Tian, Zhichao Gu, Zhiyuan Wang, Xin Liu, Zhiyong Yao, Weitao Wang, Jiaqiang Zhang, Peng Cai, Qiqing Ge, Hong Medicine (Baltimore) Research Article Recently, apatinib has been shown to be effective in treating sarcoma. This study aimed to assess the safety and efficacy of apatinib in the treatment of patients with osteosarcoma after failed of standard multimodal therapy and to compare the therapeutic effects of apatinib on osteosarcoma between high-dose group and low-dose group. A total of 27 patients with osteosarcoma who received apatinib between January 2016 and August 2017 were retrospectively reviewed. Among the 27 patients, the objective response rate (ORR) and the disease control rate (DCR) were 25.93% and 66.67%, respectively. The median of progression-free survival (m-PFS) was 3.5 months (95% confidence interval [CI], 2.5–4.8 months), and the median of overall survival (m-OS) was 9.5 months (95% CI, 7.8–10.5 months). There was no statistically significant difference in ORR (36.36% vs 18.75%), DCR (63.64% vs 68.75%), m-PFS (4.3 months [95% CI, 1.8–7 months) vs 3.35 months (95% CI, 1.8–4 months]), and m-OS (9.5 months [95% CI, 7.8–10.5 months] vs 9.4 months [95% CI, 7.8–10.8 months]) (P > .05) between the high-dose group (the average dose was 659 mg/qd) and the low-dose group (the average dose was 516 mg/qd). Most of the adverse events (AEs) were in grade 1 or grade 2. The main AEs in grade 3 were hypertension, rash, weight loss, hand-foot syndrome, and diarrhea. Apatinib is safe and effective in the treatment of advanced osteosarcoma. We recommend that the initial dose of apatinib should be 500 mg/qd in the treatment of osteosarcoma. Wolters Kluwer Health 2019-05-13 /pmc/articles/PMC6531132/ /pubmed/31083265 http://dx.doi.org/10.1097/MD.0000000000015650 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Tian, Zhichao
Gu, Zhiyuan
Wang, Xin
Liu, Zhiyong
Yao, Weitao
Wang, Jiaqiang
Zhang, Peng
Cai, Qiqing
Ge, Hong
Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study
title Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study
title_full Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study
title_fullStr Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study
title_full_unstemmed Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study
title_short Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study
title_sort efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: an observational study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531132/
https://www.ncbi.nlm.nih.gov/pubmed/31083265
http://dx.doi.org/10.1097/MD.0000000000015650
work_keys_str_mv AT tianzhichao efficacyandsafetyofapatinibintreatmentofosteosarcomaafterfailedstandardmultimodaltherapyanobservationalstudy
AT guzhiyuan efficacyandsafetyofapatinibintreatmentofosteosarcomaafterfailedstandardmultimodaltherapyanobservationalstudy
AT wangxin efficacyandsafetyofapatinibintreatmentofosteosarcomaafterfailedstandardmultimodaltherapyanobservationalstudy
AT liuzhiyong efficacyandsafetyofapatinibintreatmentofosteosarcomaafterfailedstandardmultimodaltherapyanobservationalstudy
AT yaoweitao efficacyandsafetyofapatinibintreatmentofosteosarcomaafterfailedstandardmultimodaltherapyanobservationalstudy
AT wangjiaqiang efficacyandsafetyofapatinibintreatmentofosteosarcomaafterfailedstandardmultimodaltherapyanobservationalstudy
AT zhangpeng efficacyandsafetyofapatinibintreatmentofosteosarcomaafterfailedstandardmultimodaltherapyanobservationalstudy
AT caiqiqing efficacyandsafetyofapatinibintreatmentofosteosarcomaafterfailedstandardmultimodaltherapyanobservationalstudy
AT gehong efficacyandsafetyofapatinibintreatmentofosteosarcomaafterfailedstandardmultimodaltherapyanobservationalstudy